AGLE
|Aeglea Bio Therapeutics Inc
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
48.63M
Volume
Open
Previous Close
52-Week High
52-Week Low
About Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 defic...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Jeffrey M. Goldberg
Employees:69
Headquarters:Austin, USA
Website:www.aeglea.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions